Tricyclo(6.3.1.02,5)dodecan-1-ol, 4,4,8-trimethyl-, (1R,2S,5R,8S)-
| Common Name: |
Tricyclo(6.3.1.02,5)dodecan-1-ol, 4,4,8-trimethyl-, (1R,2S,5R,8S)- |
| IUPAC Name: |
(1R,2S,5R,8S)-4,4,8-trimethyltricyclo[6.3.1.02,5]dodecan-1-ol |
| Molecular Formula: |
C7H10O |
| SMILES: |
CC1(CC2C1CCC3(CCCC2(C3)O)C)C |
| Inchi: |
1S/C15H26O/c1-13(2)9-12-11(13)5-8-14(3)6-4-7-15(12,16)10-14/h11-12,16H,4-10H2,1-3H3/t11-,12+,14+,15-/m1/s1 |
| Inchi Key: |
FUQAYSQLAOJBBC-PAPYEOQZSA-N |
| Cas No: |
56747-96-7 |
| Alcohols |
| Cyclic |
| Hydrocarbons |
| Name |
Value |
| Lipinski Violations |
0 |
| Ghose Violations |
3 |
| Veber Violations |
0 |
| Egan Violations |
0 |
| Muegge Violations |
2 |
| Name |
Value |
| Molecular Weight (g/mol) |
110.15 |
| Mass (g/mol) |
222.198 |
| Molar Refractivity |
35.02 |
| Net Charge |
|
| HBD |
|
| HBA |
1 |
| Rt Bonds |
3 |
| Rings |
3 |
| TPSA |
17.07 |
| Hetero Atoms |
1 |
| Heavy Atoms |
8 |
| Aromatic Heavy Atoms |
0 |
| Melting Point (°C) |
|
| Boiling Point (°C@760.00mm Hg) |
282.00 to 283.00 |
| Vapor Pressure (mmHg@25.00 °C) |
0.00036 |
| Vapor Density (Air =1) |
|
| Fraction Csp3 |
0.29 |
| LogP |
3.754 |
| iLOGP |
1.83 |
| XLOGP3 |
1.62 |
| WLOGP |
1.71 |
| MLOGP |
1.54 |
| ESOL Log S |
-1.35 |
| ESOL Solubility (mg/ml) |
4.97 |
| ESOL Solubility (mol/l) |
0.045 |
| ESOL Class: esol_class |
Very soluble |
| Ali Log S |
-1.59 |
| Ali Solubility (mg/ml) |
2.83 |
| Ali Solubility (mol/l) |
0.03 |
| Ali Class |
Very soluble |
| Silicos-IT LogSw |
-0.74 |
| Silicos-IT Solubility (mg/ml) |
20.2 |
| Silicos-IT Solubility (mol/l) |
0.18 |
| Silicos-IT Class |
Soluble |
| Name |
Value |
| GI Absorption |
High |
| BBB Permeable |
1 |
| PgP Substrate |
0 |
| Log Kp (cm/s) |
-5.82 |
| Bioavailability Score |
0.55 |
| Caco2 |
1 |
| Human Intestinal Absorption |
1 |
| Plasm Protein Binding |
0.918 |
| CYP1A2 Inhibitor |
0 |
| CYP2C19 Inhibitor |
0 |
| CYP2C9 Inhibitor |
0 |
| CYP2D6 inhibitor |
0 |
| CYP3A4 inhibitor |
0 |
| Ames mutagenesis |
0 |
| Acute Oral Toxicity |
3.513 |
| Carcinogenicity (Binary) |
0 |
| Carcinogenicity (Trinary) |
Non-required |
| Eye Irritation |
1 |
| Hepatotoxicity |
0 |
| Androgen Receptor Binding |
1 |
| Aromatase Binding |
0 |
| Estrogen Receptor Binding |
0 |
| Glucocorticoid Receptor Binding |
0 |
| Thyroid Receptor Binding |
0 |
| BRCP inhibitor |
0 |
| BSEP inhibitor |
0 |
| OATP1B1 inhibitor |
1 |
| OATP1B3 inhibitor |
1 |
| OATP2B1 inhibitor |
0 |
| OCT1 inhibitor |
0 |
| OCT2 inhibitor |
0 |
